Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma
H. Barailler(Centre Hospitalier Universitaire de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), S. Prey(Université de Bordeaux), Guillemette Salomon, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), E. Gérard(Université de Bordeaux), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), C. Mertens(Université de Bordeaux), M. Beylot‐Barry(Université de Bordeaux)
Cited by 6
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k